
Reunion Neuroscience Investor Relations Material
Latest events

Q3 2023
Reunion Neuroscience
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Reunion Neuroscience Inc
Access all reports
Reunion Neuroscience Inc. is a biotechnology company focused on developing innovative treatments for mental health conditions, with a particular emphasis on psychedelic-inspired therapies. The company’s lead programs are aimed at addressing major depressive disorder and other mental health challenges using novel compounds derived from psychedelics. Reunion Neuroscience seeks to advance clinical research and leverage its proprietary technologies to offer new treatment options for patients where traditional therapies may have limited effectiveness. The company is headquartered in Toronto, Canada, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
REUN
Country
🇺🇸 United States